F071 Skin-environmental Interface: Dermatologic Challenges of Our Changing Climate and Environment
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Climate change is an existential threat. With greater intensity and frequency of extreme weather events, serious health consequences are occurring now and threaten future generations. Dermatologists are uniquely positioned to advocate for public health, educate patients on the cutaneous manifestations of climate change, and create innovative solutions for mitigation. This session will highlight how climate change and pollution influence infectious, inflammatory, and autoimmune skin diseases with attention to disproportionately affected populations. This forum will provide learners with knowledge of key health impacts, tools to build sustainable practices, and opportunities for advocacy and engagement.
LEARNING OBJECTIVES
Examine the scientific basis of climate change and its impacts on cutaneous disease and the practice of dermatology.
Define the impacts of global warming, climate change, and pollution on cutaneous disease and recognize the vulnerable populations that are disproportionately affected by these.
Implement strategies to reduce our professional carbon footprint and identify opportunities for climate advocacy.
SCHEDULE
7:30 PM
Introduction and Overview of the Impacts of Climate Change on Health, Equity, and Healthcare
Eva R. Parker, MD, FAAD
7:50 PM
Climate Advocacy for Dermatologists
David P. Fivenson, MD, FAAD
8:05 PM
Stemming the Rising Tide: Antibiotic Resistance and Climate Change
Nathan Archer
8:20 PM
Forever Chemicals in Dermatology
Annika Belzer, MD
8:35 PM
Microplastics in Dermatology
Dennis Niebel
8:50 PM
Reducing Red Bag Waste in Your Practice
Divya Kumar Sharma, MD
9:05 PM
The Effects of Heat and Pollution on Autoinflammatory Skin Disease
Alexandra P Charrow, MD, FAAD
9:20 PM
Q&A
SPEAKERS
Nathan Archer
Annika Belzer, MD
Alexandra P Charrow, MD, FAAD
David P. Fivenson, MD, FAAD
Dennis Niebel
Eva R. Parker, MD, FAAD
Divya Kumar Sharma, MD
HANDOUTS
SPEAKER DISCLOSURES
Nathan Archer
No financial relationships exist with ineligible companies.
Annika Belzer, MD
No financial relationships exist with ineligible companies.
Alexandra P Charrow, MD, FAAD
Avalo – Consultant (1099 relationship)(Fees); Dermatology Foundation – Investigator(Grants/Research Funding); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Incyte Corporation – Advisory Board(Fees), Investigator(No Compensation Received); Insmed – Investigator(No Compensation Received); Insmed Incorporated – Investigator(No Compensation Received); Novartis Pharmaceuticals Corp. – Advisory Board(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(No Compensation Received); Sonoma Biotherapeutics – Investigator(No Compensation Received); UCB Pharma – Advisory Board(Honoraria); Wedbush Securities – Consultant (1099 relationship)(Honoraria);
David P. Fivenson, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Biogen – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Celldex – Investigator(Grants/Research Funding); Eli Lilly and Company – Investigator(Grants/Research Funding), Speaker(Honoraria); Gerson Lehrman Group – Consultant(Fees); Incyte – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding); Ingenix – Investigator(Grants/Research Funding); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria), Investigator(Grants/Research Funding); L.E.K. Consulting – Consultant(Fees); LEO Pharma, US – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); Symbio – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding);
Dennis Niebel
AbbVie – Advisory Board(Honoraria), Investigator(Fees), Speaker(Honoraria); Almirall – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Amgen – Speaker(Honoraria); AstraZeneca – Investigator(Fees); Biogen – Speaker(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria), Speaker(Honoraria); Eli Lilly – Speaker(Honoraria); Incyte – Advisory Board(Honoraria), Speaker(Honoraria); Janssen-Cilag – Advisory Board(Honoraria), Speaker(Honoraria); Leo Pharma Inc. – Advisory Board(Honoraria), Speaker(Honoraria); Novartis – Investigator(Grants/Research Funding), Speaker(Honoraria); Pfizer Inc. – Speaker(Honoraria); Regeneron – Speaker(Honoraria); Sanofi – Speaker(Honoraria); UCB Pharma – Speaker(Honoraria);
Eva R. Parker, MD, FAAD
L'Oreal – Advisory Board(Honoraria), Speaker(Honoraria); Magellan Health – Consultant (1099 relationship)(Honoraria); Trend Sourcing – Consultant (1099 relationship)(Honoraria);
Divya Kumar Sharma, MD
No financial relationships exist with ineligible companies.